Published in Pharm Res on May 25, 2011
Mix to validate: a facile, reversible PEGylation for fast screening of potential therapeutic proteins in vivo. Angew Chem Int Ed Engl (2013) 0.75
Nano-Armoring of Enzymes: Rational Design of Polymer-Wrapped Enzymes. Methods Enzymol (2017) 0.75
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
PEGylation, successful approach to drug delivery. Drug Discov Today (2005) 4.56
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev (2003) 2.78
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev (2009) 1.53
State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release (2011) 1.47
PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem (2005) 1.27
Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol (2006) 1.23
Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem (2008) 1.07
Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. ChemMedChem (2011) 1.07
Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev (2007) 1.06
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther (2008) 1.06
Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug Chem (2011) 1.06
Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev (2007) 1.05
The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem (2010) 1.05
Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther (2013) 1.04
Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors. Antimicrob Agents Chemother (2011) 1.03
Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J Control Release (2008) 1.02
Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? J Control Release (2007) 1.01
Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses (2003) 1.01
HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection. J Immunol (2008) 0.99
Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev (2002) 0.98
PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today (Barc) (2009) 0.96
Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem (2007) 0.94
Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm (2011) 0.94
Structural and dynamic features of the MutT protein in the recognition of nucleotides with the mutagenic 8-oxoguanine base. J Biol Chem (2009) 0.93
Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. J Control Release (2002) 0.90
Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates. J Control Release (2010) 0.89
Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging. J Biol Chem (2008) 0.87
A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins (2007) 0.87
Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation. Biochemistry (2006) 0.86
HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Proteins (2012) 0.85
Solid-state nanopore detection of protein complexes: applications in healthcare and protein kinetics. Small (2012) 0.84
Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. J Biol Chem (2003) 0.84
Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif (2005) 0.84
Covalent conjugation of poly(ethylene glycol) to proteins and peptides: strategies and methods. Methods Mol Biol (2011) 0.83
Click chemistry in peptide-based drug design. Molecules (2013) 0.82
Conjugates of peptides and proteins to polyethylene glycols. Methods Mol Biol (2004) 0.82
Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly. Cytokine (2008) 0.82
Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake. Biomacromolecules (2006) 0.82
Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules (2005) 0.81
PEGylation of the antimicrobial peptide nisin A: problems and perspectives. Farmaco (2003) 0.81
Cytokine recognition by human interleukin 5 receptor. Vitam Horm (2005) 0.81
Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin. J Med Chem (2004) 0.81
Histaminase PEGylation: preparation and characterization of a new bioconjugate for therapeutic application. J Control Release (2006) 0.81
Synthesis, characterization and preliminary cytotoxicity assays of poly(ethylene glycol)-malonato-Pt-DACH conjugates. Eur J Med Chem (2003) 0.80
A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone. J Control Release (2011) 0.80
Conjugation of hyaluronan to proteins. Carbohydr Polym (2012) 0.80
Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg Med Chem (2004) 0.80
Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1. Antimicrob Agents Chemother (2013) 0.80
Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF). Curr Pharm Des (2002) 0.79
Selective alkylation and acylation of alpha and epsilon amino groups with PEG in a somatostatin analogue: tailored chemistry for optimized bioconjugates. Bioconjug Chem (2002) 0.79
Receptor epitope usage by an interleukin-5 mimetic peptide. J Biol Chem (2005) 0.79
Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J (2006) 0.79
Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor. J Control Release (2012) 0.78
Solution NMR structure investigation for releasing mechanism of neocarzinostatin chromophore from the holoprotein. J Biol Chem (2005) 0.78
Detection of sites of infection in mice using 99mTc-labeled PN(2)S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study. Nucl Med Biol (2009) 0.78
Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha. Biopolymers (2004) 0.78
Recruitment pharmacophore for interleukin 5 receptor alpha antagonism. Biopolymers (2007) 0.78
Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG. Bioconjug Chem (2009) 0.78
Chemical and enzymatic site specific PEGylation of hGH. Bioconjug Chem (2013) 0.78
Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. J Med Chem (2009) 0.77
Inulin-D-α-tocopherol succinate (INVITE) nanomicelles as a platform for effective intravenous administration of curcumin. Biomacromolecules (2015) 0.77
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. Biomaterials (2013) 0.77
Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics. J Chem Inf Model (2016) 0.77
Second-Generation Pharmaceutical Proteins-EUFEPS Workshop on Optimizing Biotech Medicines. IDrugs (2007) 0.76
A new PEG-beta-alanine active derivative for releasable protein conjugation. Bioconjug Chem (2008) 0.76
Modular, self-assembling peptide linkers for stable and regenerable carbon nanotube biosensor interfaces. J Mol Recognit (2006) 0.76
Highly efficient technetium-99m labeling procedure based on the conjugation of N-[N-(3-diphenylphosphinopropionyl)glycyl]cysteine ligand with poly(ethylene glycol). Bioconjug Chem (2004) 0.76
Structure-based rationale for interleukin 5 receptor antagonism. Curr Pharm Des (2008) 0.76
Proteins, recognition networks and developing interfaces for macromolecular biosensing. J Mol Recognit (2004) 0.76
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anticancer Drugs (2007) 0.75
Biosensor analysis of receptor-ligand interactions. Methods Mol Biol (2004) 0.75
Stabilization of a supplemental digestive enzyme by post-translational engineering using chemically-activated polyethylene glycol. Biotechnol Lett (2010) 0.75
Coiled coil miniprotein randomization on phage leads to charge pattern mimicry of the receptor recognition determinant of interleukin 5. J Mol Recognit (2002) 0.75
Enzymatic formation of PEGylated oligonucleotides. Bioconjug Chem (2014) 0.75
A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor α. Biochemistry (2011) 0.75
PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery. Eur J Pharm Biopharm (2012) 0.75
An improved procedure for the synthesis of branched polyethylene glycols (PEGs) with the reporter dipeptide Met-betaAla for protein conjugation. Bioorg Med Chem Lett (2002) 0.75
Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues. Bioconjug Chem (2016) 0.75
Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β. Biochemistry (2015) 0.75
Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring. Org Biomol Chem (2017) 0.75
PEG-metronidazole conjugates: synthesis, in vitro and in vivo properties. Farmaco (2005) 0.75
Efficient and chemoselective N-acylation of 10-amino-7-ethyl camptothecin with poly(ethylene glycol). Bioorg Med Chem Lett (2004) 0.75
Thiol-Activated Anticancer Agents: The State of the Art. Anticancer Agents Med Chem (2017) 0.75